Oocyte donation in 61 patients.
P F Serhal, I L Craft
https://pubmed.ncbi.nlm.nih.gov/2566746/Actively Recruiting
Led by Copenhagen University Hospital, Hvidovre · Updated on 2026-04-13
462
Participants Needed
6
Research Sites
30 weeks
Total Duration
This research investigates the causes and risks of pre-eclampsia in women who become pregnant after fertility treatments involving oocyte donation. The study compares two groups women pregnant after oocyte donation and women pregnant after IVF using their own eggs. The study aims to understand immune and vascular factors involved in pre-eclampsia and to evaluate pregnancy and newborn outcomes in these women. Participants are followed throughout pregnancy with regular blood samples, blood pressure checks, clinical visits, and ultrasound exams. Early pregnancy visits include informed consent and baseline data collection. Follow-up visits occur at gestational weeks 12-14, 18-20, 28, 34, and 38, with blood samples and clinical assessments. Blood pressure is monitored weekly from week 28 until delivery. After birth, clinical outcomes such as delivery details and newborn health are recorded. Participants provide medical history and lifestyle information at enrollment. Researchers measure pre-eclampsia occurrence, biochemical markers, immune markers, and pregnancy complications. Data is collected securely, and participant confidentiality is maintained. The study includes postpartum monitoring and aims to establish a biobank for future research. Total participation spans from early pregnancy through delivery and postpartum data collection.
CONDITIONS
PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Copenhagen University Hospital, Hvidovre
Lead Sponsor
Ferring Pharmaceuticals
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 2 weeks before inclusion visit
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - From gestational week 10-12 until delivery
Participants are monitored throughout pregnancy with serial blood sampling, blood pressure measurements, clinical assessments, and ultrasound examinations to study pre-eclampsia risk and related outcomes.
6 scheduled visits: inclusion (week 10-12), weeks 12-14, 18-20, 28, 34, and 38; plus weekly blood pressure measurements starting at week 28 until delivery
Duration - From delivery to 28 days postpartum
Clinical outcome data are collected after delivery, including maternal and neonatal health information.
Data collected from medical records; no additional visits required
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
P F Serhal, I L Craft
https://pubmed.ncbi.nlm.nih.gov/2566746/Xuezi Tian, Kaveri T S Aiyer, Johanna M Kapsenberg...
https://pubmed.ncbi.nlm.nih.gov/34738274/Yueping Alex Wang, Cindy Farquhar, Elizabeth Anne Sullivan
https://pubmed.ncbi.nlm.nih.gov/22048992/Elizabeth S Ginsburg, Jenny S George
https://pubmed.ncbi.nlm.nih.gov/34253325/Kenny A Rodriguez-Wallberg, Ann-Sofie Berger, Antonia Fagerberg...
https://pubmed.ncbi.nlm.nih.gov/30626251/Ivo Brosens, Robert Pijnenborg, Lisbeth Vercruysse...
https://pubmed.ncbi.nlm.nih.gov/21094932/Lesley J Brennan, Jude S Morton, Sandra T Davidge
https://pubmed.ncbi.nlm.nih.gov/23890192/Emily Bartsch, Karyn E Medcalf, Alison L Park...
https://pubmed.ncbi.nlm.nih.gov/27094586/P Lutjen, A Trounson, J Leeton...
https://pubmed.ncbi.nlm.nih.gov/6690997/Jussara Mayrink, Renato T Souza, Francisco E Feitosa...
https://pubmed.ncbi.nlm.nih.gov/31266984/Copenhagen University Hospital, Hvidovre
Lead Sponsor
Ferring Pharmaceuticals
Collaborating Sponsor